MI rival may buy Boston Scientific

Henrietta Strickland
June 14, 2018

Its down 0.38, from 1.34 in 2017Q4. For the next one year period, the average of individual price target estimates referred by covering sell-side analysts is $32.76. The shares of Express, Inc.

BSX has been the subject of several other reports. Boston Scientific had 20 analyst reports since January 3, 2018 according to SRatingsIntel. During the past quarter, total 947,741,033 shares held by institutions with the net change of -31,729,927 shares.

In trying to determine the current valuation of Boston Scientific Corporation (NYSE:BSX) shares, we note that the Book to Market ratio of the shares stands at 0.168093. Ww Asset Mngmt has 0.12% invested in Boston Scientific Corporation (NYSE:BSX) for 92,622 shares. Ser Automobile Association has invested 0.1% in Boston Scientific Corporation (NYSE:BSX). Tci Wealth owns 2,292 shares.

Boston Scientific Corporation (NYSE:BSX) is creating a comprehensive business analysis with a goal to evaluate positive and negative sides of the company's operations. San Francisco Sentry Inv Grp (Ca) holds 7,152 shares or 0.06% of its portfolio. This public company's stock also has a beta score of 0.78. State Board Of Administration Of Florida Retirement stated it has 0.15% in Boston Scientific Corporation (NYSE:BSX).

Though it has recently stressed to investors its ability to innovate new technologies, over the years Boston Scientific has grown through acquisitions. The insider Ballinger Kevin J. sold $1.21M. 7,500 shares were sold by Butcher Arthur C, worth $225,413 on Thursday, May 10. Price Michael F reported 277,500 shares. The firm had revenue of $2.38 billion during the quarter, compared to the consensus estimate of $2.34 billion. The insider Fitzgerald Joseph Michael sold 85,227 shares worth $2.26 million.

Boston Scientific Corporation (NYSE:BSX) presently has a current ratio of 0.82. The 8 months bullish chart indicates low risk for the $46.89B company. For example, a projected EPS growth stands at 175.00% in this year, while for the next years it is estimated at 12.65%. Boston Scientific Corporation has a consensus rating of "Buy" and an average price target of $25.75.

The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The shares recently went up by 2.96% or $0.92 and now trades at $31.95. About 14.04 million shares traded or 98.82% up from the average. The Free Cash Flow Yield 5 Year Average of Boston Scientific Corporation (NYSE:BSX) is 0.016752. It has underperformed by 1.38% the S&P500.

Medical device maker Stryker Corp. has made a takeover approach to rival Boston Scientific Corp., the Wall Street Journal reported on Monday, a combination that would give Stryker a strong position in stroke-preventing heart products. BSX's profit will be $469.14 million for 23.49 P/E if the $0.34 EPS becomes a reality.

The company's earnings per share shows growth of 175.00% for the current year and expected to arrive earnings growth for the next year at 12.73%. Therefore 87% are positive. Argus now has a buy rating on the medical equipment provider's stock.

Boston Scientific, headed by US-based CEO Mike Mahoney, employs more than 3,000 in Ireland, which is home to three of its five European plants, in Galway, Cork and Clonmel, Co Tipperary. Morgan Stanley maintained it with "Overweight" rating and $33 target in Monday, March 19 report.

Boston Scientific Corporation (BSX) stock moved up 5.20% in contrast to its 20 day moving average displaying short-term an upside movement of stock. Piper Jaffray has "Buy" rating and $31.0 target. The company maintained a Gross Margin of 72.20%. The rating was maintained by Needham with "Buy" on Thursday, February 1. The firm has "Top Pick" rating by RBC Capital Markets given on Friday, January 5. Lifeplan invested 0.01% in Boston Scientific Corporation (NYSE:BSX). In this case performance of tends to percentage rate of return for a stock for a given time frame.

While looking at the Stock's Performance, Boston Scientific Corporation now shows a Weekly Performance of 4.45%, where Monthly Performance is 7.11%, Quarterly performance is 11.95%, 6 Months performance is 26.58% and yearly performance percentage is 14.48%.

Boston Scientific lags behind Medtronic and Edwards Lifesciences Corp in the heart valves market and has pinned its hopes on its updated Lotus device, set for launch in 2019, following the withdrawal of an earlier version from Europe previous year.

"If this news is accurate, it would create a roughly $24 billion medtech company, which would place it behind only Medtronic and Johnson & Johnson in total device revenue", Wells Fargo Securities analyst Lawrence Biegelsen said in a research note. It operates through three divisions: Cardiovascular, Rhythm Management, and MedSurg. It has a 447.11 P/E ratio.

Other reports by Click Lancashire

Discuss This Article